Financiere de Tubize SA
LSE:0D53
Intrinsic Value
Financiere de Tubize SA is a holding company, which engages in investing in biopharmaceuticals industry. [ Read More ]
The intrinsic value of one
0D53
stock under the Base Case scenario is
3 650.34
EUR.
Compared to the current market price of 61.8 EUR,
Financiere de Tubize SA
is
Undervalued by 98%.
Financiere de Tubize SA's market capitalization is 4.2B EUR.
0D53 stock price is 61.8 EUR.
0D53 stock price (61.8 EUR) is 98% less than its Intrinsic Value (3 650.34 EUR).
0D53 stock (19.11 EUR) is 69% less than its price (61.8 EUR). Open Relative Valuation
0D53 has upside potential of 122% compared to the average analyst price target.
Open Wall St Estimates
0D53 has positive three-year average ROE (Return on Equity): 9%. The company is efficient at transforming stockholders' equity into net income.
0D53 has positive three-year average ROIC (Return on Invested Capital): 8%. The company is efficient at using invested capital to generate operating income.
0D53's ROE (Return on Equity) has decreased in the last 3 years from 10% to 4%.
0D53's ROE (Return on Equity) for the past 12 months is very low and is equal to 4%.
0D53's ROIC (Return on Invested Capital) has decreased in the last 3 years from 9% to 0%.
0D53's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 0%.
0D53's Revenue has dropped by 99% over the past 12 months.
0D53 has positive Operating Income for the last twelve months.
0D53 has positive Net Income for the last twelve months.
0D53 has negative Free Cash Flow for the last twelve months.
0D53 has positive Gross Profit for the last twelve months.
0D53's Revenue has been falling by 85% per year for the last 3 years.
0D53's short-term liabilties (49m EUR) exceed its short-term assets (2m EUR).
0D53's long-term assets (2B EUR) exceed its long-term liabilties (49m EUR).
0D53's D/E (Debt to Equity) is very low and is equal to 0.
0D53's Altman Z-Score is very high and is equal to 40.04.
Fundamental Analysis
Financiere de Tubize SA
Balance Sheet Decomposition
Financiere de Tubize SA
| Current Assets | 1.6m |
| Cash & Short-Term Investments | 1.6m |
| Other Current Assets | 60.4k |
| Non-Current Assets | 1.9B |
| Long-Term Investments | 1.9B |
| Current Liabilities | 48.6m |
| Accounts Payable | 225k |
| Other Current Liabilities | 48.4m |
Earnings Waterfall
Financiere de Tubize SA
|
Revenue
|
993.3k
EUR
|
|
Cost of Revenue
|
-430
EUR
|
|
Gross Profit
|
992.9k
EUR
|
|
Operating Expenses
|
2.5k
EUR
|
|
Operating Income
|
995.4k
EUR
|
|
Other Expenses
|
92.1m
EUR
|
|
Net Income
|
93.1m
EUR
|
Free Cash Flow Analysis
Financiere de Tubize SA
0D53 Profitability Score
Profitability Due Diligence
Financiere de Tubize SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
Financiere de Tubize SA's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
0D53 Solvency Score
Solvency Due Diligence
Financiere de Tubize SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Financiere de Tubize SA's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
0D53 Price Targets Summary
Financiere de Tubize SA
According to Wall Street analysts, the average 1-year price target for
0D53
is 137.25 EUR
with a low forecast of 135.9 EUR and a high forecast of 141.28 EUR.
Shareholder Return
TUB Price
Financiere de Tubize SA
| Average Annual Return | 6.24% |
| Standard Deviation of Annual Returns | 21.48% |
| Max Drawdown | -39% |
| Market Capitalization | 4.2B EUR |
| Shares Outstanding | 44 512 600 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Financiere de Tubize SA
Country
Industry
Market Cap
Dividend Yield
Description
Financiere de Tubize SA is a holding company, which engages in investing in biopharmaceuticals industry. The company is headquartered in Brussels, Bruxelles-Capitale. The firm holds minor capital in UCB SA. UCB is a Belgian pharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. UCB, together with its subsidiaries, has research and development facilities in Belgium, Germany, Japan, the United Kingdom and the United States.
You don't have any saved screeners yet
